These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26855094)

  • 1. Sexual Desire and Hormonal Contraception.
    Boozalis A; Tutlam NT; Chrisman Robbins C; Peipert JF
    Obstet Gynecol; 2016 Mar; 127(3):563-572. PubMed ID: 26855094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
    Hofmeyr GJ; Singata-Madliki M; Batting J; Balakrishna Y; Morroni C
    BMC Womens Health; 2024 Mar; 24(1):167. PubMed ID: 38459552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.
    Hofmeyr GJ; Singata-Madliki M; Batting J; Steyn P; Thomas KK; Issema R; Beesham I; Mbatsane E; Morrison C; Deese J; Smit J; Philip N; Palanee-Phillips T; Reddy K; Onono M; Mastro TD; Baeten JM;
    PLoS One; 2024; 19(5):e0299802. PubMed ID: 38722832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An exploratory analysis of contraceptive method choice and symptoms of depression in adolescent females initiating prescription contraception.
    Francis J; Presser L; Malbon K; Braun-Courville D; Linares LO
    Contraception; 2015 Apr; 91(4):336-43. PubMed ID: 25553873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familiarity and acceptability of long-acting reversible contraception and contraceptive choice.
    Paul R; Huysman BC; Maddipati R; Madden T
    Am J Obstet Gynecol; 2020 Apr; 222(4S):S884.e1-S884.e9. PubMed ID: 31838124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copper containing intra-uterine devices versus depot progestogens for contraception.
    Hofmeyr GJ; Singata M; Lawrie TA
    Cochrane Database Syst Rev; 2010 Jun; 2010(6):CD007043. PubMed ID: 20556773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial.
    Hofmeyr GJ; Singata-Madliki M; Lawrie TA; Bergel E; Temmerman M
    Reprod Health; 2016 Apr; 13():42. PubMed ID: 27091008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.
    Morrison CS; Hofmeyr GJ; Thomas KK; Rees H; Philip N; Palanee-Phillips T; Nanda K; Nair G; Onono M; Mastro TD; Lind M; Heffron R; Edward V; Deese J; Beksinska M; Beesham I; Stringer JSA; Baeten JM; Ahmed K;
    AIDS Res Hum Retroviruses; 2020 Aug; 36(8):632-640. PubMed ID: 32394723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postpartum contraception: initiation and effectiveness in a large universal healthcare system.
    Brunson MR; Klein DA; Olsen CH; Weir LF; Roberts TA
    Am J Obstet Gynecol; 2017 Jul; 217(1):55.e1-55.e9. PubMed ID: 28257962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa.
    Beesham I; Bosman S; Beksinska M; Scoville CW; Smit J; Nanda K
    Contraception; 2022 Apr; 108():37-43. PubMed ID: 34848180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.
    Mugo NR; Stalter RM; Heffron R; Rees H; Scoville CW; Morrison C; Kourtis AP; Bukusi E; Beksinka M; Philip NM; Beesham I; Deese J; Edward V; Donnell D; Baeten JM;
    Clin Infect Dis; 2022 Sep; 75(4):586-595. PubMed ID: 34910143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
    Singata-Madliki M; Lawrie TA; Balakrishna Y; d'Hellencourt FC; Hofmeyr GJ
    Reprod Health; 2021 Sep; 18(1):192. PubMed ID: 34587971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
    Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
    PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of contraceptive initiation on vaginal microbiota.
    Achilles SL; Austin MN; Meyn LA; Mhlanga F; Chirenje ZM; Hillier SL
    Am J Obstet Gynecol; 2018 Jun; 218(6):622.e1-622.e10. PubMed ID: 29505773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder.
    Berenson AB; Asem H; Tan A; Wilkinson GS
    Obstet Gynecol; 2011 Dec; 118(6):1331-1336. PubMed ID: 22105263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant.
    Tanko RF; Bunjun R; Dabee S; Jaumdally SZ; Onono M; Nair G; Palanee-Phillips T; Harryparsad R; Happel AU; Gamieldien H; Qumbelo Y; Sinkala M; Scoville CW; Heller K; Baeten JM; Bosinger SE; Burgener A; Heffron R; Jaspan HB; Passmore JAS
    J Infect Dis; 2022 Sep; 226(5):907-919. PubMed ID: 35263421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey of young women's perceptions of the influence of the Levonorgestrel-Intrauterine System or copper-intrauterine device on sexual desire.
    Malmborg A; Brynhildsen J; Hammar M
    Sex Reprod Healthc; 2019 Oct; 21():75-80. PubMed ID: 31395237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body weight and body composition of depot medroxyprogesterone acetate users.
    Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
    Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.